PK Interaction of Azilsartan and Rosuvastatin in Healthy Volunteers

Phase 1, randomised, open-label trial of azilsartan and rosuvastatin in hypertension (HTN) and hypercholesterolemia (2 arms), sponsored by Celltrion. Primary endpoints: Area Under the Curve over the Dosing Interval at Steady State at 24 hours and Maximum Plasma Concentration at Steady State at 24 hours. Started Jul 2021; status: completed.